Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$3.93 - $7.7 $19,363 - $37,937
-4,927 Closed
0 $0
Q4 2021

Jun 21, 2023

BUY
$7.1 - $12.82 $34,981 - $63,164
4,927 New
4,927 $34,000
Q4 2021

Mar 30, 2023

SELL
$7.1 - $12.82 $11,523 - $20,806
-1,623 Reduced 24.78%
4,927 $34,000
Q4 2021

Feb 15, 2022

SELL
$7.1 - $12.82 $11,523 - $20,806
-1,623 Reduced 24.78%
4,927 $35,000
Q3 2021

Jun 21, 2023

BUY
$7.64 - $12.49 $50,042 - $81,809
6,550 New
6,550 $71,000
Q3 2021

Mar 30, 2023

SELL
$7.64 - $12.49 $32,431 - $53,020
-4,245 Reduced 39.32%
6,550 $71,000
Q3 2021

Nov 15, 2021

SELL
$7.64 - $12.49 $32,431 - $53,020
-4,245 Reduced 39.32%
6,550 $72,000
Q2 2021

Jun 21, 2023

BUY
$8.68 - $27.49 $93,700 - $296,754
10,795 New
10,795 $93,000
Q2 2021

Mar 30, 2023

BUY
$8.68 - $27.49 $11,422 - $36,176
1,316 Added 13.88%
10,795 $93,000
Q2 2021

Aug 16, 2021

BUY
$8.68 - $27.49 $93,622 - $296,507
10,786 Added 119844.44%
10,795 $94,000
Q1 2021

Jun 26, 2023

BUY
$12.0 - $27.64 $113,748 - $261,999
9,479 New
9,479 $144 Million
Q1 2021

Mar 30, 2023

SELL
$12.0 - $27.64 $12,636 - $29,104
-1,053 Reduced 10.0%
9,479 $144,000
Q1 2021

May 14, 2021

SELL
$12.0 - $27.64 $126,276 - $290,855
-10,523 Reduced 99.91%
9 $144,000
Q4 2020

Jun 22, 2023

BUY
$11.05 - $16.62 $116,378 - $175,041
10,532 New
10,532 $122,000
Q3 2020

Jun 26, 2023

BUY
$11.69 - $14.54 $123,119 - $153,135
10,532 New
10,532 $134,000
Q2 2020

Jun 26, 2023

BUY
$9.75 - $17.6 $102,687 - $185,363
10,532 New
10,532 $157,000
Q1 2020

Jul 12, 2023

BUY
$7.54 - $17.05 $79,411 - $179,570
10,532 New
10,532 $121,000
Q1 2020

Mar 30, 2023

BUY
$7.54 - $17.05 $11,634 - $26,308
1,543 Added 17.17%
10,532 $121,000
Q1 2020

May 15, 2020

BUY
$7.54 - $17.05 $11,634 - $26,308
1,543 Added 17.17%
10,532 $122,000
Q4 2019

Jul 12, 2023

BUY
$6.71 - $9.55 $60,316 - $85,844
8,989 New
8,989 $82,000
Q4 2019

Mar 30, 2023

SELL
$6.71 - $9.55 $10,762 - $15,318
-1,604 Reduced 15.14%
8,989 $82,000
Q4 2019

Feb 14, 2020

SELL
$6.71 - $9.55 $10,762 - $15,318
-1,604 Reduced 15.14%
8,989 $82,000
Q3 2019

Jul 12, 2023

BUY
$6.0 - $9.6 $63,558 - $101,692
10,593 New
10,593 $94,000
Q3 2019

Mar 30, 2023

BUY
$6.0 - $9.6 $63,558 - $101,692
10,593 New
10,593 $94,000
Q3 2019

Nov 14, 2019

BUY
$6.0 - $9.6 $63,558 - $101,692
10,593 New
10,593 $95,000

Others Institutions Holding CVM

About CEL SCI CORP


  • Ticker CVM
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,367,500
  • Market Cap $30.4M
  • Description
  • CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...
More about CVM
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.